Cardiorenal and endocrine effects of synthetic canine BNP1‐32 in dogs with compensated congestive heart failure caused by myxomatous mitral valve disease

Abstract

Background The effects of synthetic brain natriuretic peptide (BNP1‐32) on cardiorenal and renin angiotensin aldosterone system in dogs with naturally occurring congestive heart failure (CHF) are unknown. Objectives To evaluate the cardiorenal and endocrine effects of SC administered synthetic canine BNP1‐32, with or without furosemide, in dogs with CHF caused by myxomatous mitral valve disease (MMVD). Animals Seven client‐owned male dogs with compensated American College of Veterinary Internal Medicine stage C CHF caused by MMVD on chronic treatment with furosemide, benazepril, and pimobendan. Methods A single‐dose, crossover, pilot study. Each dog received a dose of BNP1‐32 (5 μg/kg), furosemide (2 mg/kg), and both BNP1‐32/furosemide (5 μg/kg and 2 mg/kg, respectively) SC with a 2‐week washout period among each treatment. Between‐ and within‐treatment effects were evaluated using linear mixed modeling with restricted maximum likelihood estimation and evaluation of least square differences. Results Rapid absorption of BNP1‐32 and a corresponding rise in urinary cyclic guanosine monophosphate excretion was observed at 1‐2 hours after any treatment containing BNP1‐32 (P < .05). However, BNP1‐32 did not influence measured cardiorenal variables. Plasma aldosterone concentrations were below quantifiable levels in majority of the samples. Conclusions and Clinical Importance No beneficial cardiorenal effects were detected. It is possible that dogs with chronic CHF have a reduction in natriuretic peptide responsiveness.

Determination of the chronic toxicity of preparation “Bendamin” on laboratory animals

“…Кардіологія це один із напрямків ветеринарної медицини, який найбільш інтенсивно розвивається. За останні роки було проведено кілька значних досліджень в області лікування серцевої недостатності, були введені нові методи діагностики, виявлено генетичні особливості окремих патологій та з'явилися нові лікарські засоби, наприклад: пімобендан, поліненасичені жирні кислоти, силденафіл, левосимендан, торасемід, небіволол, лізиноприл, клопідогрель та деякі інші (Zhulikova, 2016;Varkholiak, 2016;Tjostheim et al, 2019;Yata et al, 2019). Разом з тим, даних про застосування нових терапевтичних засобів за серцево-судинної патології недостатньо.…”

News

“…Several peak bodies have produced guidelines on care of dogs and cats at different life stages, including the American Association of Feline Practitioners (AAFP) 1, 2 , the American Animal Hospital Association (AAHA) 3,4 , and the Australian Veterinary Association 5 . All of these recommend regular health checks (annual for adults, and every 6 months for seniors and older), with diagnostic testing included, especially as animals age.…”

“…In addition to examining existing treatment options for CHF, Mariko also studied the potential of the natriuretic peptide system as a therapeutic target in dogs with CHF. In a recently published article, 4 she identified that the cardiorenal effects of BNP1-32 (a type of natriuretic peptide) were diminished in dogs with CHF caused by myxomatous mitral valve disease. This suggested defects in what is essentially a protective mechanism in the context of CHF and is a finding that prompts further investigations into therapeutics targeting this system.…”

The influence of the preparation “Bendamin” on the morphological and biochemical indices of blood of rats in experimental modeling of heart failure

“…According to the classification of Professor G. V. Domrachev, in domestic animals, cardiovascular pathology is divided into diseases of the myocardium, pericardium, endocardium and diseases of the blood vessels. There is a close relationship between the above pathologies, age and animal breeds (Undhad et al, 2012;Varkholiak, 2016;Zhulikova, 2016;Yata et al, 2019).…”